independent analyst report prepared by eg capital

Independent Analyst Report prepared by eG Capital
Date Published: 22-02-2006

------------------------------------------------------

Valuation per share: $0.04 - $0.08 * Stock data Share price: $0.02 52 week range: $0.019 - $0.039 Market capitalisation: $6.248 m Shares outstanding: 312,400,712 ** Cash: $1.75 m Enterprise value: $4.498 m Average daily volume: 825,051

�� Visiomed has a unique, patented device, the Funhaler, that markedly improves childrens’ compliance in taking their asthma medication properly.

We have valued the company at $0.08 per share using a DCF analysis, which comprises $0.04 for the Funhaler alone and $0.04 for application of the core technology to allied products: peak flow meters and spirometers .


For full report .. http://www.visiomed.com.au/media/eG%20Capital%20Report%20February%202006.pdf